AUTL:NASDAQ, Autolus Therapeutics plc

AUTL stock overview

Autolus Therapeutics plc (AUTL:NASDAQ) closed at $1.09 on November 17, 2026, down 4.39% on the day. The stock trades 57.8% below its 52-week high of $2.58 and 1.9% above its 52-week low of $1.07. Over the past year, it lost 15.5%. Autolus Therapeutics plc is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).

Key figures

Price
$1.09
Day change
-4.39%
Volume
2,097,974
Average volume
2,118,264
Market cap
290M+
52-week range
$1.07 – $2.58
50-day average
$1.68
200-day average
$1.66

Price action over the past year

In 252 trading sessions since November 17, 2025, AUTL closed higher on 109 days (43%). Its best day was August 3, 2026 (+22.15%) and its worst was January 12, 2026 (-17.13%). The stock moved 10% or more in a single session 9 times. It opened at least 5% above the previous day's high 2 times.

Recent signals

AUTL news

About Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company. It is engaged in the development of next-generation programmed T cell therapies for the treatment of cancer. The company's pipeline includes AUTO1, AUTO2, AUTO3, AUTO4, and AUTO6.

Similar stocks

Find more stocks like AUTL with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.